Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Related Citations for PubMed (Select 23816044)

1.

Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.

Norman DD, Ibezim A, Scott WE, White S, Parrill AL, Baker DL.

Bioorg Med Chem. 2013 Sep 1;21(17):5548-60. doi: 10.1016/j.bmc.2013.05.061. Epub 2013 Jun 11.

PMID:
23816044
2.

Ligand-based autotaxin pharmacophore models reflect structure-based docking results.

Mize CD, Abbott AM, Gacasan SB, Parrill AL, Baker DL.

J Mol Graph Model. 2011 Nov;31:76-86. doi: 10.1016/j.jmgm.2011.09.004. Epub 2011 Sep 18.

3.

Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.

Fells JI, Lee SC, Fujiwara Y, Norman DD, Lim KG, Tsukahara R, Liu J, Patil R, Miller DD, Kirby RJ, Nelson S, Seibel W, Papoian R, Parrill AL, Baker DL, Bittman R, Tigyi G.

Mol Pharmacol. 2013 Sep;84(3):415-24. doi: 10.1124/mol.113.087080. Epub 2013 Jun 21.

4.

Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.

Fells JI, Lee SC, Norman DD, Tsukahara R, Kirby JR, Nelson S, Seibel W, Papoian R, Patil R, Miller DD, Parrill AL, Pham TC, Baker DL, Bittman R, Tigyi G.

FEBS J. 2014 Feb;281(4):1017-28. doi: 10.1111/febs.12674. Epub 2014 Jan 15.

5.

Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.

Parrill AL, Echols U, Nguyen T, Pham TC, Hoeglund A, Baker DL.

Bioorg Med Chem. 2008 Feb 15;16(4):1784-95. Epub 2007 Nov 12.

PMID:
18036821
6.

Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.

Kawaguchi M, Okabe T, Okudaira S, Nishimasu H, Ishitani R, Kojima H, Nureki O, Aoki J, Nagano T.

ACS Chem Biol. 2013 Aug 16;8(8):1713-21. doi: 10.1021/cb400150c. Epub 2013 Jun 3.

PMID:
23688339
7.

Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.

van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH.

J Biol Chem. 2005 Jun 3;280(22):21155-61. Epub 2005 Mar 15.

8.

Structure-based design of novel boronic acid-based inhibitors of autotaxin.

Albers HM, Hendrickx LJ, van Tol RJ, Hausmann J, Perrakis A, Ovaa H.

J Med Chem. 2011 Jul 14;54(13):4619-26. doi: 10.1021/jm200310q. Epub 2011 Jun 9.

9.

Structural basis of substrate discrimination and integrin binding by autotaxin.

Hausmann J, Kamtekar S, Christodoulou E, Day JE, Wu T, Fulkerson Z, Albers HM, van Meeteren LA, Houben AJ, van Zeijl L, Jansen S, Andries M, Hall T, Pegg LE, Benson TE, Kasiem M, Harlos K, Kooi CW, Smyth SS, Ovaa H, Bollen M, Morris AJ, Moolenaar WH, Perrakis A.

Nat Struct Mol Biol. 2011 Feb;18(2):198-204. doi: 10.1038/nsmb.1980. Epub 2011 Jan 16.

10.

Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.

North EJ, Osborne DA, Bridson PK, Baker DL, Parrill AL.

Bioorg Med Chem. 2009 May 1;17(9):3433-42. doi: 10.1016/j.bmc.2009.03.030. Epub 2009 Mar 21.

11.

Optimization of a pipemidic acid autotaxin inhibitor.

Hoeglund AB, Bostic HE, Howard AL, Wanjala IW, Best MD, Baker DL, Parrill AL.

J Med Chem. 2010 Feb 11;53(3):1056-66. doi: 10.1021/jm9012328.

PMID:
20041668
12.

Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells.

Fulkerson Z, Wu T, Sunkara M, Kooi CV, Morris AJ, Smyth SS.

J Biol Chem. 2011 Oct 7;286(40):34654-63. doi: 10.1074/jbc.M111.276725. Epub 2011 Aug 10.

13.

Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT.

Mol Cancer Ther. 2008 Oct;7(10):3352-62. doi: 10.1158/1535-7163.MCT-08-0463.

14.

Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.

North EJ, Howard AL, Wanjala IW, Pham TC, Baker DL, Parrill AL.

J Med Chem. 2010 Apr 22;53(8):3095-105. doi: 10.1021/jm901718z.

PMID:
20349977
15.

Autotaxin inhibitors: a patent review.

Barbayianni E, Magrioti V, Moutevelis-Minakakis P, Kokotos G.

Expert Opin Ther Pat. 2013 Sep;23(9):1123-32. doi: 10.1517/13543776.2013.796364. Epub 2013 May 6. Review.

PMID:
23641951
16.

alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.

Cui P, McCalmont WF, Tomsig JL, Lynch KR, Macdonald TL.

Bioorg Med Chem. 2008 Mar 1;16(5):2212-25. Epub 2007 Dec 4.

17.

Biological roles of lysophosphatidic acid signaling through its production by autotaxin.

Okudaira S, Yukiura H, Aoki J.

Biochimie. 2010 Jun;92(6):698-706. doi: 10.1016/j.biochi.2010.04.015. Epub 2010 Apr 22. Review.

PMID:
20417246
18.

Autotaxin--an LPA producing enzyme with diverse functions.

Nakanaga K, Hama K, Aoki J.

J Biochem. 2010 Jul;148(1):13-24. doi: 10.1093/jb/mvq052. Epub 2010 May 21. Review.

PMID:
20495010
19.

Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O.

PLoS One. 2010 Mar 17;5(3):e9741. doi: 10.1371/journal.pone.0009741.

20.

Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.

Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H.

J Biol Chem. 2006 Sep 1;281(35):25822-30. Epub 2006 Jul 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk